Ethan Rowin, MD
Cardiovascular Disease · Boston, MANPI 1578790283
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Pfizer at 45.5% of the total. Reporting peaked in 2024 at $5,500 and has fallen 97.4% since, to $142 in 2025.
Across 13 payments — averaging $511.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Irhythm Technologies, Inc.$3K
- Vertex$408
- Medtronic$142
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30
- Amgen$20
Across 26 payments — averaging $32,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Irhythm Technologies, Inc.$562K
- Pfizer$260K
- Withings, Inc.$15K
- Novartis$8K
- Celltrion, Inc.$654
What the payments were for
- Consulting fees$3,43352%
- Speaking & faculty fees$3,00045%
- Food & beverage$2213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $3,030 |
| Irhythm Technologies, Inc. | 2 | $3,025 |
| Vertex | 1 | $408 |
| Medtronic | 4 | $142 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $30 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIO XT Patch$2,500
- ZIO Patch$525
- COBALT DR MRI SURESCAN$103
How this compares
$6,655 in reported general payments places this provider in the 70th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 21 | $296 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.